# **ABL Biotechnologies Limited**

7

Regd. Office: No.71, Nehru Nagar, Industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041
Statement of Standalone/Consolidated Financial Results for the Quarter Ended 30/09/2013

(Rs. in Lak

PART I		State	ment of Stand	alone/Consoli	dated Finansia	Statement of Standalone/Consolidated Finansial Results for the Quarter Env		Sed 30/09/2013					
						Compensation	Consenanting 3 months anded	Year to Date figures for current	ures for current	Year to Date figures for the	gures for the	Drawing to Year anded	
		S months ended	S BOOM	rieceum y o	Pleceumy 3 months enveo	in the pre	in the previous year	Period	Period ended	previous year enned	em en men		
	Particulars	30.09.2013	2013	30.06	30.06.2013	30.00	30.09.2012	30.00	30.09.2013	30.09.2012	2012	31.03.2013	Auditor
		Unaudited standalone	Unaudited consolidated	Unaudited standalone	Unaudited consolidated	Unaudited standalone	Unaudited consolidated	Audited standalone	Unaudited Consolidated	standalone	Consolidated	standalone	consolidat
•	Income from operations										3		
•	(a) Net Sales/Income from Operations			0.00	0.00	0.00	0.00			9.00	١	0.00	
	(b) Other Operating Income	0.16	0.16	0.16	0.16			0.32	0.32			0.65	
	Total income from operations (net)	0.16	0.16	0.16	0.16	9.00	0.00	0.32	0,32	0.00	0.00	0.00	
N	Expenditure												
	(a) Increase /⊡ecrease in Stock in trade and work in												
•	b) Consumption on Raw materials									3	200		
	c) Product De velopment Cost					0.8	0.00			5.5			
	d) conversion / other charges					<u> </u>							
	e) Purchase of traded goods											1.50	
	f) Employee benefits expense											3.90	
	9) Acti					0.09	0.09			0.09	0.09	0.00	
	i) Legal/Consultancy Expenses	0.04	0.04	0.07	0.07	0.25	0.25	0.11	0.11	0.32	0.32		
	j) Office Renovation											9.10	
	k) bangalore shifting charges										001	001	
	i) Communication Cost	0.01	0.01			0.03	0.03	3	0.01	1	0.03		
	m) Printing & Stationery							1					
	m) Analysis, resulty occess out	5			200	0.70	0.70	0.90	0.90	1.50	1.50	0.85	
•	i) 7 7 7 COLACOURAGE	9		1	1							0.00	
	p) Power, Fuel & Gas choes											0.00	
	q) Consumables												
	r) Audit Fees					0.25	5 0.25			Ī		0.16	
	s) Bank Charges	0.02	0.02					0.02	0.02		0.00		
	t)Service Cost for labour									0.00		T	
	u) Others					1 70	1 70	3	400				
	v) Depreciation and amortisation expense	2.20	2.20							1			
	w) Preliminary expenses written off	1.23	1.23	1.23	1.23								
	<ul> <li>c) Othe expenses (Arry item exceeding 10% or treatons to be total expenses relating to continuing operations to be shown seperately)</li> </ul>		-		!	-						18 67	
	Total expenses	3.60	3.60	3.90	3.90	4.26	4.26	.90	1	ة قا	֓֞֜֜֜֜֜֜֜֜֜֜֜֜֓֓֓֓֜֜֟֜֜֜֜֟֓֓֓֓֓֓֜֟֜֜֜֜֟֓֓֓֓֓֡֓֜֜֜֜֜֜֜֜		

	and property of the state of th		Statem	ent of Standals	one / Consolid	Statement of Standalone / Consolidated Unaudited / Audit		Its for the Quar	ed Results for the Quarter Ended 30/09/2013	2013			<b>3</b>
Page 2	ABL Differentiation Common	3 months ended	ended	Preceding 3 months ended	onths ended	Corresponding 3 months		Year to Date figures fo Period ended	ended Year to Date figures for current Year to Date figures for the Period ended previous year ended	Year to Date figures for to previous year ended	igures for the sar ended	Previous Year end	gar end
						3	20.00.0043	30 09 2013	2013	30.06.2012	2012	31.03.2013	2013
	Particulars	30.09.2013	2013	30.06.2013	2013	92.00	ı	diam's	Sau Million	Audiend	Audited	Audited	À
		_	Unaudited	Audited	Audited	Audited	Audited	standalone	Consolidated	-	L <u>R</u>	╇	00TB0
		standalone	CONSCIONATED	Stat March 16			14 281	(7.48)	7.18	(8.16)	(8,16)	(17.92)	
•	Profit /Loss from Operations before other income,	(3.44)	(3,44)	(3.74)	(3.74)	(4.26)	(97.4)	(1.10)				2	
·	finance costs and financial items (1-2)	2	2	9	8	0.00	0.00	0.00	0.00	0.00	9.00	6.5	
	Other Income	0.00	9.00	0.00					7 10	œ A	(B. 16)	(17.92)	
da .	Profit / (Loss) from ordinary activities before	(3.44)	(3.44)	(3.74)	(3.74)	(4.26)	(4.26)	(7.10)	(2.70)			3	
g.	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00		0.00				
7	Profit / (Loss) from ordinary activities before finance costs but before exceptional items (5-	(3.44)	(3.44)	(3.74)	(3.74)	(4.26)	(4.26)	(7.18)	(7.18)	(8.16)	(8.16)	(17.92)	
	6)				3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
<b></b>	Exceptional items - write offs	0.00						(7.18)	(7.18)	(8.16)	(8.16)	(17.92)	
9	iProfit / Loss Itom officery acceptance acceptance and including acceptance acceptance and including acceptance acceptanc	(3.44)	(3.44)	(3.74)		]		08	0.80	0.00	0.00	0.00	
<del>-</del>	Tax expense	0.00	0.00	0.00	0.00	0.00						(17.92)	
	Net Profit / Loss from ordinary activities after tax	(3.44)	(3.44)	(3.74)	(3.74)	(4.26)	(4.26)	(7.18)	(r.1a)	(6.16)	9.0	1	
-	(9-10)			3	000	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
12	Extraordinary literus (literus cas experies inc.	0.00	0.00				(A)	(7.18)	(7.18)	(8.16)	(8.16)	(17.92)	
t	Net Profit / Loss for the period (11-12)	(3.44)	(3.44)	(3.74)	(3./4)	(4.20)							
i													
				-		_	_						

	ABL Biotechnologies Limited		Stateme	ent of Standal	one / Consolid	Statement of Standalone / Consolidated Unaudited / Audit	/ Audited Resu	ts for the Quar	led Results for the Quarter Ended 30/09/2013	2013		I o	(Rs. 15
rage (		3 months ended	ended	Preceding 3 months ended		Corresponding in the pre	Corresponding 3 months ended Year to Date figures for current in the previous year Period ended	Year to Date figures fo Period ended		Year to Date figures for the previous year ended	igures for the sar ended	Previous Year en	sar en
		300	3	30 08 2013	2013	30.06	30.06.2012	30.06.2013	2013	30.06.2012	2012	31.03.2013	2013
	T COL AND COMMENT OF		Unaudited	Audited	Audited	Audited	Audited	Audited	Unaudited Consolidated	Audione	Audited Consolidated	Audited standalone	SUSC SIN
		standalone	consolidated	Standards	CONTROLLOGIC					ž	23	2	
=	Share of Profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2 5	3 6		
	Minority imterest*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.0	9.0	
	Net Profit / (Loss) after taxes, minority interest	à	3	(3.74)	(3.74)	(4.26)	(4.26)	(7 18)	(7.18)	(8.16)	(8.16)	(17.92)	
ő	and share of profit / (loss) of associates ( 13+14+15)*	(i	(i	3									
17	Paid-up equity share capital (Face Value of the Shar shall be included) Face Value Rs. 10/- per share	820.00	820.00	820. <b>00</b>	820.00	820.00	820.00	820.00	820.00	820.00	820.00	820.00	
Ö	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						•				-		
	Earning's Per Share (before extraordinary items) of Rs/- each) (not annualised):				<del>".</del>				i		ò	6	
<u></u>	(a) Basic (b) Diluted	(0.04)	(0.04)	(0.05)	(0.05)	(0.05)	(0.03)	(0.05)	(0.06)	(0.03)	(0.03)		
	Earnings Per Share (after extraordinary items) (of Rs/- sach) (not annualised):								•	000	<i>(</i> 0 03)	0.22	
ų	(a) Basic (b) Diluted	(0.04)	(6.Q.	(0.05)	(0.05) (0.05)	(0.03	(0.03)	(0.05)	(0.05)				
	See accompanying note to the financial results												

o Part II	ABL Biotechnologies Limited	3 month	a and the			Select Information Corresponding 3 months	ormation for a months ex	ă ₹	or the quarter ended :			
		3 months ended	s ended	Preceding 3 r	Preceding 3 months ended	Correspond in the	32	sponding 3 months ended in the previous year	fing 3 months ended Year to Date fig previous year Period	ended Year to Date figures for current r Period ended		Sing 3 months ended Year to Date figures for current Year to Date figures for the previous year ended
	Particulars	30.09.2013	2013	30.06	30.06.2013		0.0	30.06.2012		90.06.2012 30.06.2013	30.06.2013	
		Unaudited standalone	Unaudited consolidated	Audited standalone	Audited consolidated	Audited standalone	3 x	Audited one Consolidated		Audited Consolidated	Audited Audited Unaudited Audited Consolidated standalone Consolidated standalone	Audited Audited Unaudited Consolidated standalone Consolidated
<b>→</b> >	PARTICULARS OF SHAREHOLDING Public Shareholding											
	- Number of shares	815100G	8151000	8151000	8151000	~	8151000	3151000 8151000	8	8151000	8151000 8151000	8151000 8151000 8151000
	- Percentage of shareholding	99.40%	99.40%	99.40%	99.40%		99,40%	98.40% 98.40%		99.40% 99.40%	99.40% 99.40% 99.40%	99.40% 99.40% 99.40% 98.40%
N	Promoters and promoter group Shareholding**											
	a) Pledged/Encumbered  - Number of shares	<u>N</u>	<u>z</u>	Z	Z.		<u>Z</u>	Nii		N.	Na Na	Na Na Na
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the Company) b) Non-en-cumbered											
	- Number of Shares	49000	49000	49000	49000		49000	49000 49000		49000	49000 49000	49000 49000 49000
	- Percentage of shares (as a% of the total shar eholding of promoter and promoter group)	100%	100%	100%	100%		100%	100% 100%	•	100%	100% 100%	100% 100% 100%
	<ul> <li>Percentage of shares (as a % of the total share capital of the company)</li> </ul>	0.60%	0.60%	0,60%	0.60%		0.60%	0.60% 0.60%		0.60% 0.60%	0.80%	0.80% 0.80% 0.60%

Part	INVESTOR COMPLAINTS	3 months ended (30/09/2013)
8		
	Peniding at the beginning of the quarter	N.
	Received during the quarter	N. C.
	Disprosed of during the quarter	2
	Remaining unresolved at the end of the quarter	<u>Z</u>

# Notes

- (1) Above re-sults were taken on record by the Board of Directors at their meeting held on 13/11/2013
- (2) Previous year/quarter figures have been regrouped where necessary.
  (3) ABL Research Pvt. Ltd. a 100% subsdiary of ABL Biotechnologies started activities in Research Projects effective and reported under Preliminary Operative expenses. in the project to Rs. 68.94 lakhs. These expenses being in the nature of Project expenses are being accumulated April 201 0 and incurred expenses of Rs. 18.92 Lakhs during April - September 2013 bringing the total expenses

For ABL Biotechnologies Limited 1 a Salar

Date : 13/11\_/2013 Place: Chennai

Managing Director

ABL Biotechnologies Limited

Regd. Office: No.71, Nehra Nagar, Industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041

	<del></del>	_	_		_		O1	_		<b></b>			4	٤	ა	N	) )						>	•			
TOTAL - EQUITY AND LIABILITIES	Sub-Cotal - Current Habilities	(a) Snort-term provisions	(c) Cale content labitues	(c) Other current lighting	(b) Trade payables ( Sundry Creditors)	(a) Short-term borrowings	Current liabilities	Sub-total - Non-current liabi lities	(d) Long-term provisions	(c) Other long-term liabilities	(b) Deferred tax liabilities (net)	(a) Long-term borrowings	Non-current liabilities	mil sonty interest		Share application money pending allotment		Sub-total- Shareholders' funds	(C) Money received agains t share warrants	(D) Reserves and surplus	(a) Share capital	Shareholders' funds	EQUITY AND LIABILITIES				Statement of ASSe to or Liabilities.
449,462,110	137,426,090		47,318,697	40,909,149	10,070,440	43 148 744		128,625,907				128,625,907						183,410,113		101,410,113	82,000,000		Rs.	Standalone	Si	Septemi	
456,541,406	138,582,704		47,737,803	47,696,657	45,746,244	12110111		134.548.579				134,548,579		10				183,410,113			82,000,000		Rs.	Consolidated	Unaudited	September 30, 2013	
450,145,860	137,421,090		47,313,697	46,959,149	43,148,244		1000	128 596 957				128.596.957						184,127,813	$\neg$	_	82,000,000		Rs.	Standalone	Ą	March	Period
455,250,518	138,212,241		47,548,839	47,515,158	43,148,244		102,010,404	132 010 454	\$			132 910 454		10				184,127,813		102 127	82,000,000	ļ	Į,	Consolidated	Audited	March 31, 2013	Period ended on
450,780,681	138,132,152		46,953,667	47,388,240	43,790,245		775'160'171	177 007 722			141,001,122	Т						184.751.007	102,734,007	T	82 000 000	Ş	+	Standak	Una	Septemb	
453,692,237	141,043,698	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	47 196 201	47.482.442	46,365,055		127,897,522			!	775'169'171	177 007 577		10			T	184 751 007	/00/TC//20T	Т	T	Z.	Consolination	Consolidated	Unaudited	September 30, 2012	

1

ABL Biotechnologies Limited

Regd. Office: No.71, Nehru Nagar, industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041

					•••			2		_						_	Φ.					
TOTAL - ASSETS	Su b-total - Current Assets	(f) Other current assets	(e) Short-term loans and advances	(d) Cash and cash equivalents	(c) Trade receivables	(b) Inventories	(a) Current in vestments	Current assets	Sub-total - Non-current Assets	(f) Other non-current assets( Prel Exp)	(e) Long-term loans and advances	(d) Deferre taix assets (net)	(c) Non -current investments	(b) Goodwill on consolidation*	(a) Fixed assets	Non-currents assets	ASSETS					Staternent of Assets & Liabilities.
449,462,110	86,570,864		81,980,020	1,387,731	3,203,113				362,891,246	2,535,811			13,099,990		347,255,445				Standalone	Una	Septembe	
456,541,406 450,145,856	86,856,212		82,036,985	1,366,114	3,203,113		250,000		369,685,194	9,429,749	į		13,000,000		347,255,445				Consolidated	Unaudited	September 30, 2013	
450,145,856	86,608,487		81,980,020	1,387,659	3,240,808			:	369,685,194 363,537,369	2,781,811			13,099,990		347,655,568				Standalone	Aus	March :	Period (
455,250,516	86,810,925		81,990,021	1,330,096	3,240,808		250,000		368,439,591	7,784,022			13,000,000		347,655,569				Consolidated	Audited	March 31, 2013	Period ended on
450,780,681	86,589,498		81,980,022	1,448,668	3,160,808				364,191,183	3,027,210			13,099,990		348,063,983				Standalone	Unal	Septembe	
453,692,237	86,841,912		82,240,022	1,441,082	3,160,808				366,850,325	5,786,342			13,000,000		348,063,983		:	į	Consolidated	Unaudited	September 30, 2012	

## PRATAPKARAN PAUL & Co. CHARTERED ACCOUNTANTS

New No. 63, Old No. 31, Kamaraj Avenue First Street, Adyar, Chennai - 600 020.

Tel: 24912619, 24460445, 24913902.

E-mail: pkpandco@gmail.com

# Limited Review Report to First Financial Services Limited

We have reviewed the accompanying statement of unaudited financial results of ABL Biotechnologies Limited for the period from 01.07.2013 to 30.09.2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material

For Pratapkaran Paul & Co., **Chartered Accountants** 

Dharmara] Partner

M. No. 224216

P. Dhu Ray

Date :13.11.2013 Place: Chennai